VILAZODONE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C26H27N5O2
Molecular Weight	441.5249
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=O)C1=CC2=C(O1)C=CC(=C2)N3CCN(CCCCC4=CNC5=C4C=C(C=C5)C#N)CC3

InChI

InChIKey=SGEGOXDYSFKCPT-UHFFFAOYSA-N

InChI=1S/C26H27N5O2/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32)

HIDE SMILES / InChI

Molecular Formula	C26H27N5O2
Molecular Weight	441.5249
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022567s019lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9098681

Vilazodone is a serotonergic antidepressant. The mechanism of the antidepressant effect of vilazodone is not fully understood but is thought to be related to its inhancement of serotonergic activity in the CNS through selective inhibition of serotonin reuptake. Vilazodone is also a partial agonist at serotonergic 5-HT1A receptors; however, the net result of this action on serotonergic transmission and its role in vilazodone’s antidepressant effect are unknown. The side effects include activation of mania/hypomania in patients with bipolar disorder, seizures can occur with treatment in patients with a seizure disorder.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium-dependent serotonin transporter 41 Target ID: P31645 Gene ID: 6532.0 Gene Symbol: SLC6A4 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12183683	Inhibitor 8504		0.5 nM [IC50]
Serotonin 1a (5-HT1a) receptor 177 Target ID: CHEMBL214 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022567s019lbl.pdf	Agonist 2752		0.2 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Major depressive disorder 179 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022567s019lbl.pdf	Primary		Approved 8583	VIIBRYD Approved Use Indicated for the treatment of major depressive disorder (MDD) Launch Date 2011

C_max

Value	Dose	Co-administered	Analyte	Population
156 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022567s021lbl.pdf	40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		VILAZODONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Co-administered	Analyte	Population
1645 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022567s021lbl.pdf	40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		VILAZODONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
25 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022567s021lbl.pdf	40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		VILAZODONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022567s021lbl.pdf	40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		VILAZODONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inducer 1087 inhibitor 2252	substrate 1193 inducer 440 inhibitor 2438	substrate 1388 inducer 109 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2B6 926 CYP1A2 2153 CYP2C19 2057 CYP2E1 1060 CYP2C8 1057 P-gp 1741	CYP2C19 1119 CYP2C8 810 CYP1A2 1197 CYP2A6 626 CYP2E1 729	CYP1A1 151 CYP1A2 832 CYP2A6 86 CYP2C19 329 CYP2E1 131 CYP3A5 92 CYP2C8 198

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=40, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=42 Page: 58, (ClinPharm) 19, 22-23, 37-40, 90	moderate [IC50 2.8 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=42 Page: 58, (ClinPharm) 19, 23, 37-39, 41-42, 90	moderate [Ki 7.37 uM]
CYP1A1 272	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=23, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=49 Page: 58, (ClinPharm) 23, 47-49	no
CYP2A6 911	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=23, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=49 Page: 58, (ClinPharm) 23	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=23, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=49 Page: 58, (ClinPharm) 23, 47-49	no
CYP2C8 1117	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=18 Page: (ClinPharm) 18	no
CYP2E1 1146	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=23, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=49 Page: 58, (ClinPharm) 18, 23, 47-49	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58 Page: 58.0	no
CYP3A5 201	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=23, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=49 Page: 58, (ClinPharm) 23, 47-49	no
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=23, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=49, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=92 Page: 58, (ClinPharm) 18, 23, 47-49, 89-94	no	no (co-administration study) Comment: Human hepatocytes (two donors), Little/no increases were observed in mRNA expression.; Coadministration of vilazodone (20 mg QD for 10 days) with caffeine (100 mg QD on Day 10) to healthy subjects resulted in a small (9%) decrease in paraxanthine/caffeine plasma ratio (8-h post dose). Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=23, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=49, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=92 Page: 58, (ClinPharm) 18, 23, 47-49, 89-94
CYP2C9 2497	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=23, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=49, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=93 Page: 58, (ClinPharm) 18, 23, 47-49, 89-94	no	no (co-administration study) Comment: Human hepatocytes (two donors), Little/no increases were observed in mRNA expression.; Coadministration of vilazodone (20 mg QD for 10 days) with flurbiprofen (50 mg QD on Day 10) to healthy subjects resulted no effect in CYP2C9 activity (4'-hydroxyflurbiprofen urinal recovery (0-8 hr)/flurbiprofen AUC0-8 (L/h)). Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=23, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=49, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=93 Page: 58, (ClinPharm) 18, 23, 47-49, 89-94
CYP2C19 2141	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=23, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=49, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=93 Page: 58, (ClinPharm) 18, 23, 47-49, 89-94	no	weak (co-administration study) Comment: Human hepatocytes (two donors), Little/no increases were observed in mRNA expression.; Coadministration of vilazodone (20 mg QD for 10 days) with mephenytoin (100 mg QD on Day 10) to healthy subjects resulted in a small (11%) increase in mephenytoin biotransformation. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=23, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=49, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=93 Page: 58, (ClinPharm) 18, 23, 47-49, 89-94
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=19, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=46 Page: (ClinPharm) 16, 19, 42-45, 45-47, 90	unlikely [IC50 >6.3 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=22, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=40 Page: 58, (ClinPharm) 22, 37-40, 42-45	weak [IC50 68 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=41 Page: 58, (ClinPharm) 22-23, 41-42, 90	weak [Ki 24 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=41 Page: 58, (ClinPharm) 22-23, 41-42, 90	weak [Ki 81.7 uM]
CYP2D6 2546	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=18, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=49, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=92 Page: (ClinPharm) 18, 47-49, 89-94	weak	no (co-administration study) Comment: 2.4-fold mRNA expression (60 hr incubation with human hepatocytes from two donors); Coadministration of vilazodone (20 mg QD for 10 days) with debrisoquine (10 mg QD on Day 10) to healthy subjects resulted in a small (10%) increase in 4'-hydroxydebrisoquine/debrisoquine total urinary recovery ratio (0-8 hr post dose). Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=18, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=49, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=92 Page: (ClinPharm) 18, 47-49, 89-94
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=18, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=49, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=92 Page: (ClinPharm) 18, 47-49, 89-94	weak	no (co-administration study) Comment: 2.2-fold mRNA expression (60 hr incubation with human hepatocytes from two donors); Coadministration of vilazodone (20 mg QD for 10 days) with nifedipine (20 mg QD on Day 8) to healthy subjects resulted in no change in Nifedipine AUC0-inf and a small increase (13%) in Cmax. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=18, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=49, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=92 Page: (ClinPharm) 18, 47-49, 89-94
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022567s021lbl.pdf#page=12 Page: (Label) 12	weak	yes (co-administration study) Comment: Coadministration of Vilazodone slightly increased Digoxin (P-gp substrate) AUC and Cmax (less than 25%). Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022567s021lbl.pdf#page=12 Page: (Label) 12

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2C8 810	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58 Page: 58.0	likely
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=39 Page: (ClinPharm) 22, 37-39	likely
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=39, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=84 Page: 58, (ClinPharm) 14, 18, 21, 22, 23, 37-39, 82-84	major	yes (co-administration study) Comment: Ketoconazole (200 mg QD for 13 days), a strong CYP3A4 inhibitor, increased vilazodone (5 mg or 10 mg QD on Day 4) systemic exposure (AUC0-t) by 42% (5 mg), 51% (10 mg), and Cmax by 48% (5 mg), 38% (10 mg), Human liver microsomes (specific inhibitor: troleandomycin 50 mcM) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=39, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=84 Page: 58, (ClinPharm) 14, 18, 21, 22, 23, 37-39, 82-84
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=39 Page: 58, (ClinPharm) 18, 22, 37-39	minor
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=58, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=39 Page: 58, (ClinPharm) 18, 22, 37-39	minor
CYP2E1 729	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=39 Page: (ClinPharm) 22, 37-39	minor
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=39 Page: (ClinPharm) 22, 37-39	unlikely
CYP2A6 626	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdf#page=39 Page: (ClinPharm) 22, 37-39	unlikely

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000PharmR.pdf#page=48 Page: 48.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:70707	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:70707
ChemicalBook	CB31011682	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB31011682
eMolecules	36473276	https://www.emolecules.com/cgi-bin/more?vid=36473276
MolPort	MolPort-005-933-319	https://www.molport.com/shop/molecule-link/MolPort-005-933-319
ZINC	ZINC000001542113	http://zinc15.docking.org/substances/ZINC000001542113

PubMed

Title	Date	PubMed
Issues encountered in recent attempts to develop novel antidepressant agents.	2015-05	25762133
Psychotropic exposures in pediatric patients: Symptomatic iloperidone and vilazodone ingestions.	2015-03	25646639
Identification of hydrolytic and isomeric N-oxide degradants of vilazodone by on line LC-ESI-MS/MS and APCI-MS.	2015-01	25459935
Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.	2014-12	25249164
A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.	2014-12	25224953
Bioavailability comparison of a new form of vilazodone XVII to IV in beagles using liquid chromatography/mass spectrometry.	2014-12	24853720
Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.	2014-11	25470094
Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder.	2014-11	24978955
A validated LC-MS/MS method for the rapid quantification of vilazodone in rat plasma: application to a pharmacokinetic study.	2014-09	24937809

Patents

Sample Use Guides

In Vivo Use Guide

Recommended target dosage: 20 mg to 40 mg once daily with food. To titrate: start with initial dosage of 10 mg once daily for 7 days, followed by 20 mg once daily. The dose may be increased up to 40 mg once daily after a minimum of 7 days between dosage increases. Prior to initiating VIIBRYD, screen for bipolar disorder.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:08:48 GMT 2025` Edited by `admin` on `Mon Mar 31 18:08:48 GMT 2025`
Record UNII	S239O2OOV3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EMD 515259

Preferred Name

English

VILAZODONE

Official Name

English

VILAZODONE [MI]

Common Name

English

EMD-515259

Code

English

2-BENZOFURANCARBOXAMIDE, 5-(4-(4-(5-CYANO-1H-INDOL-3-YL)BUTYL)-1-PIPERAZINYL)-

Systematic Name

English

5-{4-[4-(5-Cyano-1H-indol-3-yl)butyl]piperazin-1-yl}benzofuran-2-carboxamide

Systematic Name

English

VILAZODONE [MART.]

Common Name

English

vilazodone [INN]

Common Name

English

VILAZODONE [VANDF]

Common Name

English

EMD 68843 BASE

Code

English

5-(4-(4-(5-CYANOINDOL-3-YL)BUTYL)-1-PIPERAZINYL)-2-BENZOFURANCARBOXAMIDE

Systematic Name

English

Vilazodone [WHO-DD]

Common Name

English

VILAZODONE [USAN]

Common Name

English

EMD-68843 BASE

Common Name

English

EMD-68-843

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C265